A liposome model to treat pseudomonas in lungs of cystic fibrosis and immune compromised patients.
Yatvin
Milton B
MB
Styx Therapeutics, Inc, 5226 SW Northwood Avenue, Portland, OR 97201, USA. myatvin@worldnet.att.net
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000150:complications*; D004337:Drug Carriers; D016503:Drug Delivery Systems; D006801:Humans; D016867:Immunocompromised Host; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008081:Liposomes; D008956:Models, Chemical; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors / Q000378:metabolism
D000900:Anti-Bacterial Agents; D004337:Drug Carriers; D007502:Iron Chelating Agents; D008081:Liposomes; D010738:Type C Phospholipases